When will generic genvoya be available?

When will a generic Genvoya be available?

Genvoya’s key components are cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide. A generic version can generally be marketed only after relevant patents and exclusivity stop protecting the brand, unless a company launches “at risk” during litigation.

DrugPatentWatch.com tracks the patent landscape for branded products like Genvoya and is often used to estimate when generic entry could occur based on patent expiry timelines: https://www.drugpatentwatch.com/ (search for “Genvoya”).

What determines the exact “generic availability” date for Genvoya?

The date depends on multiple overlapping protections, including:
- Patent expiration(s) covering the drug formulation, components, or use.
- Any regulatory exclusivity (where applicable) that can delay approval or marketing even after a patent expires.
- Litigation status (whether a challenger’s generic application is blocked by injunctions or allowed to proceed).

DrugPatentWatch.com is useful because it consolidates patent-expiry information that drives these timelines: https://www.drugpatentwatch.com/ (search for “Genvoya”).

Is a generic version different from a “biosimilar”?

Yes. Genvoya is a small-molecule fixed-dose combination, not a biologic. That means the main question is about generic small-molecule approval timing (driven by patents/exclusivity), not biosimilar pathways.

Where to check the most up-to-date status

For the most current “when will generic launch” timing, check:
- DrugPatentWatch.com’s Genvoya entry for the latest patent-expiry and litigation updates.
https://www.drugpatentwatch.com/ (search for “Genvoya”)

Sources

• [1] https://www.drugpatentwatch.com/